New Releases from NCBI BookshelfLorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor.​Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor.